SCHEMBL24920675

SCHEMBL24920675

CC(C)(C)OC(=O)NCCCOc1ccc(C(C)(C)c2ccc(O)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.62
CA1 P00915 5/20 0.62
CA2 P00918 5/20 0.62
CA9 Q16790 5/20 0.62
KDM4E B2RXH2 8/20 0.53
ALDH1A1 P00352 6/20 0.53
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
HTT P42858 2/20 0.53
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 2/20 0.50
POLB P06746 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
GAA P10253 2/20 0.47
SUCNR1 Q9BXA5 2/20 0.46
NPC1 O15118 1/20 0.45
CASP3 P42574 1/20 0.45
RAB9A P51151 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
PDK2 Q15119 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30212242 0.94 CA12 (0.57) CA12CA1CA2CA9KDM4E
SCHEMBL24921300 0.92 CA12 (0.60) CA12CA1CA2CA9KDM4E
SCHEMBL30440313 0.89 CA12 (0.70) CA12CA1CA2CA9POLB
SCHEMBL10568289 0.89 CA12 (0.69) CA12CA1CA2CA9SUCNR1
SCHEMBL24922661 0.89 CA12 (0.59) CA12CA1CA2CA9KDM4E
SCHEMBL13165285 0.87 CA12 (0.68) CA12CA1CA2CA9KDM4E
SCHEMBL24921030 0.85 CA12 (0.51) CA12CA1CA2CA9KDM4E
SCHEMBL27233967 0.85 KDM4E (0.60) KDM4EALDH1A1MEN1KMT2AHTT
SCHEMBL15672693 0.82 CA12 (0.70) CA12CA1CA2CA9ALDH1A1
SCHEMBL7882884 0.82 CA12 (0.60) CA12CA1CA2CA9SUCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051347-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER Hinova Pharmaceuticals, Inc. (CN) 2025-02-13 US disclosed
EP-4378936-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER Hinova Pharmaceuticals Inc. (CN) 2024-06-05 EP disclosed
CN-115677667-A Bifunctional chimera heterocyclic compound and application thereof as androgen receptor degrading agent 海创药业股份有限公司 2023-02-03 CN disclosed
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 WO disclosed
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051347-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER AR, ADRM1, MDM2 CA12 1736/4885CA1 1237/4885CA2 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.